Hormonal
Adjunct treatment with once-weekly semaglutide (max 0.5 mg) induces significant weight loss in non-diabetic patients experiencing weight regain or insufficient weight loss after bariatric surgery.
If you have had bariatric surgery and are regaining weight or haven't lost enough, talk to your doctor about adding once-weekly semaglutide. This study shows it can help you lose significant weight (over 10% in 6 months) even at a lower dose (0.5 mg) than what is typically used for non-surgical obesity. It is a safe adjunct to lifestyle changes and may help you avoid more invasive revision surgery.
Our results imply a clear benefit of adjunct treatment with semaglutide in post-bariatric patients.
Why this rating
The study is a retrospective analysis with a small sample size (n=44) and lacks a control group, limiting causal inference.
Source
The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis
Anne Lautenbach et al. · Obesity Surgery · 2022
DOI 10.1007/s11695-022-06211-9
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →